Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Change in Acquisitions & Divestments (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed Change in Acquisitions & Divestments for 7 consecutive years, with $29.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Acquisitions & Divestments rose 46.54% year-over-year to $29.3 million, compared with a TTM value of $88.5 million through Dec 2025, up 2.39%, and an annual FY2025 reading of $88.5 million, up 2.39% over the prior year.
  • Change in Acquisitions & Divestments was $29.3 million for Q4 2025 at aTYR PHARMA, up from $19.0 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $33.6 million in Q3 2023 and bottomed at $2.3 million in Q1 2021.
  • Average Change in Acquisitions & Divestments over 5 years is $19.6 million, with a median of $20.3 million recorded in 2023.
  • The sharpest move saw Change in Acquisitions & Divestments tumbled 84.3% in 2021, then skyrocketed 530.43% in 2022.
  • Year by year, Change in Acquisitions & Divestments stood at $8.3 million in 2021, then surged by 238.09% to $28.1 million in 2022, then fell by 2.18% to $27.5 million in 2023, then dropped by 27.27% to $20.0 million in 2024, then surged by 46.54% to $29.3 million in 2025.
  • Business Quant data shows Change in Acquisitions & Divestments for ATYR at $29.3 million in Q4 2025, $19.0 million in Q3 2025, and $21.5 million in Q2 2025.